Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression

Alarmins in chronic noncommunicable diseases: Atherosclerosis, diabetes and cancer

(2017) Raluca M Boteanu et al.   Journal of Proteomics

Current status and future perspectives on treatment of liver metastasis in colorectal cancer

(2017) Mahdi Hussain Al Bandar et al.   ONCOLOGY REPORTS

Expression levels and clinical significance of hepsin and HMGB1 proteins in cervical carcinoma

(2017) Hui Cheng et al.   Oncology Letters

Downregulation of NPM expression by Her-2 reduces resistance of gastric cancer to oxaliplatin

(2017) Zhenni Sun et al.   Oncology Letters

Transforming growth factor-β1 contributes to oxaliplatin resistance in colorectal cancer via epithelial to mesenchymal transition

(2017) Liang Mao et al.   Oncology Letters

Metformin Improves Overall Survival of Colorectal Cancer Patients with Diabetes: A Meta-Analysis

(2017) Fanqiang Meng et al.   Journal of Diabetes Research

Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin

(2017) Armin Wiegering et al.   NEOPLASIA

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

(2017) et al.   Cancers

From tumour heterogeneity to advances in precision treatment of colorectal cancer

(2016) Cornelis J. A. Punt et al.   Nature Reviews Clinical Oncology

Metformin: An anti-diabetic drug to fight cancer

(2016) Marie Daugan et al.   PHARMACOLOGICAL RESEARCH

Mechanisms of drug resistance in colon cancer and its therapeutic strategies

(2016) Tao Hu et al.   WORLD JOURNAL OF GASTROENTEROLOGY

The association of HMGB1 expression with clinicopathological significance and prognosis in Asian patients with colorectal carcinoma: a meta-analysis and literature review

(2016) Jinming Yu et al.   OncoTargets and Therapy

Activation of PI3Kγ/Akt pathway increases cardiomyocyte HMGB1 expression in diabetic environment

(2016) Jia Song et al.   Oncotarget

Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway

(2016) Vicenç Ruiz de Porras et al.   Scientific Reports

Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk

(2016) Mei Peng et al.   Scientific Reports

HMGB1-mediated autophagy modulates sensitivity of colorectal cancer cells to oxaliplatin via MEK/ERK signaling pathway

(2015) Weijun Liu et al.   CANCER BIOLOGY & THERAPY

Fulvic Acid Attenuates Resistin-Induced Adhesion of HCT-116 Colorectal Cancer Cells to Endothelial Cells

(2015) Wen-Shih Huang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The Role of HMGB1 Signaling Pathway in the Development and Progression of Hepatocellular Carcinoma: A Review

(2015) Xuanbin Wang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

NF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progression

(2015) YI SUN et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance

(2015) E. Martinez-Balibrea et al.   MOLECULAR CANCER THERAPEUTICS

Smad4 sensitizes colorectal cancer to 5-fluorouracil through cell cycle arrest by inhibiting the PI3K/Akt/CDC2/survivin cascade

(2015) BINHAO ZHANG et al.   ONCOLOGY REPORTS

Broad targeting of resistance to apoptosis in cancer

(2015) Ramzi M. Mohammad et al.   SEMINARS IN CANCER BIOLOGY

Interference with HMGB1 increases the sensitivity to chemotherapy drugs by inhibiting HMGB1-mediated cell autophagy and inducing cell apoptosis

(2015) Ruiguang Zhang et al.   TUMOR BIOLOGY

Immunohistochemical detection of high-mobility group box 1 correlates with resistance of preoperative chemoradiotherapy for lower rectal cancer: a retrospective study

(2015) Kumiko Hongo et al.   World Journal of Surgical Oncology

Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal

(2014) L. Li et al.   CLINICAL CANCER RESEARCH

NF- B, an Active Player in Human Cancers

(2014) Y. Xia et al.   Cancer Immunology Research

HMGB1 in Cancer: Good, Bad, or Both?

(2013) R. Kang et al.   CLINICAL CANCER RESEARCH

Metabolic roles of AMPK and metformin in cancer cells

(2013) Yeon Kyung Choi et al.   MOLECULES AND CELLS

Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients

(2013) Weiling He et al.   World Journal of Surgical Oncology

Mechanisms and insights into drug resistance in cancer

(2013) Hiba Zahreddine et al.   Frontiers in Pharmacology

In vitro and in vivoanti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma

(2012) Qingqiong Luo et al.   BMC CANCER

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway

(2012) Rabbie K. Hanna et al.   GYNECOLOGIC ONCOLOGY

HMGB1 Promotes Drug Resistance in Osteosarcoma

(2011) J. Huang et al.   CANCER RESEARCH

HMGB proteins: Interactions with DNA and chromatin

(2010) Michal Štros   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Oxaliplatin responses in colorectal cancer cells are modulated by CHK2 kinase inhibitors

(2010) IM Pires et al.   BRITISH JOURNAL OF PHARMACOLOGY

Metformin inhibits P-glycoprotein expression via the NF-κB pathway and CRE transcriptional activity through AMPK activation

(2010) Hyung Gyun Kim et al.   BRITISH JOURNAL OF PHARMACOLOGY

HMGB1 release and redox regulates autophagy and apoptosis in cancer cells

(2010) D Tang et al.   ONCOGENE

Antitumor Activity of Gemcitabine and Oxaliplatin Is Augmented by Thymoquinone in Pancreatic Cancer

(2009) Sanjeev Banerjee et al.   CANCER RESEARCH